Dec 12, 2025
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving…
Dec 11, 2025
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing…
Nov 12, 2025
BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update
Jun 27, 2025
Med (Cell Press) 2025
Sep 19, 2024
Lancet Respiratory Medicine 2024
Sep 14, 2023
JNCCN 2023
Nov 16, 2025
PP01.45: Phase 3 Study of Plinabulin/Docetaxel vs. Docetaxel in 2L/3L…
Oct 23, 2025
Phase 2 study of pembrolizumab (Pemb) plus plinabulin (Plin) and…
Sep 10, 2025
Immune Activation with Plinabulin Enhances Anti-tumor Response Combining Radiation with…
Jun 30, 2020
NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) — BeyondSpring Inc.…
Jun 23, 2020
Jun 15, 2020
June 15, 2020 Met Primary Endpoint of Rate of Severe…
Jun 14, 2020
04.01.2019 American Association for Cancer Research Annual Meeting (2019) Predictive…
03.01.2019 ASCO-SITC Clinical Immuno-Oncology Symposium (2019) A Phase II Trial…
11.29.2018 American Society of Hematology (ASH) Annual Meeting (2018) Plinabulin,…
11.09.2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting (2018)…
10.22.2018 European Society for Medical Oncology (ESMO) Congress (2018) Plinabulin…
Jun 11, 2020
June 11, 2020 PROTECTIVE-2 (Study 106) Phase 3 Interim Analysis…
Email us at
Call us at
Office location